Lyme Disease Vaccine
Research Study
Researchers at NYU Langone Health-Long Island are evaluating a potential vaccine that may protect children and teens ages 5-17 against Lyme disease. Join today!
Fast Facts
lyme vaccine for ages 5-17
General Good Health
Compensation provided
Conducted in mineola, nY
About Our Research Studies
Lyme disease is an infectious disease that can be transmitted to humans through the bite of infected ticks. The most common signs and symptoms of Lyme disease include an expanding “bullseye” rash, as well as flu-like symptoms like fatigue, headache, fever, and joint and muscle pain. If left untreated, the infection can spread to other parts of the body, causing serious health issues.
Lyme disease can occur at any age; however, the age groups most affected are children 5-15 years old and adults older than 50.
The goal of this research study is to understand the safety and tolerability of a phase 3 Pfizer Lyme vaccine in healthy children between the ages of 5 and 17. Participants will be randomly assigned (like flipping a coin) to receive either the study vaccine (called VLA15) or a placebo, which is just made up of saline. Your child is 3 times more likely to receive the study vaccine than the placebo, but this study is also observer-blinded, which means that the parent, child, and doctors will not know whether the child is receiving the active vaccine or placebo.
The vaccine requires a total of 4 doses: the first 3 doses are given beginning when you join the study (“Month 0”) and then 2 and 6 months later. The last dose is given about a year after the third dose, or about 18 months after beginning the study.
As Lyme ticks spread to more areas, your child’s participation in this vaccine study can potentially help advance public health and protect future generations against Lyme disease. Join our study today!
Study Background
Lyme disease is an infectious disease that can be transmitted to humans through the bite of infected ticks. The most common signs and symptoms of Lyme disease include an expanding “bullseye” rash, as well as flu-like symptoms like fatigue, headache, fever, and joint and muscle pain. If left untreated, the infection can spread to other parts of the body, causing serious health issues.
Lyme disease can occur at any age; however, the age groups most affected are children 5-15 years old and adults older than 50.
The goal of this research study is to understand the safety and tolerability of a phase 3 Pfizer Lyme vaccine in healthy children between the ages of 5 and 17. Participants will be randomly assigned (like flipping a coin) to receive either the study vaccine (called VLA15) or a placebo, which is just made up of saline. Your child is 3 times more likely to receive the study vaccine than the placebo, but this study is also observer-blinded, which means that the parent, child, and doctors will not know whether the child is receiving the active vaccine or placebo.
The vaccine requires 3 doses: the first will be given the first month of the study, then at 3 months, and 6. A booster dose will be given about a year after the first 3 shots, at around month 18. There will be a total of 4 doses administered for both the active vaccine and placebo.
As Lyme ticks spread to more areas, your child’s participation in this vaccine study can potentially help advance public health and protect future generations against Lyme disease. Join our study today!
Additional Information
Your child may qualify for this study if they meet the following criteria.
Key Criteria:
- 5-17 years old
- In general good health
This study will involve at least 6 in-person visits and 2 telephone visits during the 2-year study period.
